In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Daxor (DXR – Research Report), with a price target of $22.00. The company’s shares closed last Tuesday at $12.00.
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 16.7% and a 46.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Milestone Scientific, and Dermata Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Daxor with a $22.00 average price target.
The company has a one-year high of $17.58 and a one-year low of $8.58. Currently, Daxor has an average volume of 26.39K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.